Evan Y. Yu, MD, discusses the therapeutic options for metastatic castration-resistant prostate cancer (mCRPC) included in the National Comprehensive Cancer Network (NCCN) guidelines, such as ...
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...
Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...
MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...
In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...
Alec Kimmelman, MD, PhD, and Shridar Ganesan, MD, PhD, discuss the institution's new molecular oncology program.
Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations ...
Panelists discuss how health care providers can optimize quality-of-life and treatment outcomes for patients with ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date ...
Bezuclastinib plus sunitinib showed favorable safety and efficacy in GIST, outperforming sunitinib alone in phase 3 Peak ...
Patients with AML aged 80 years and older face poor survival despite treatment advances, highlighting the need for improved, ...
The panelist discusses how real-world evidence for CAR T in relapsed/refractory multiple myeloma shows promising efficacy but ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback